Shares of Bristol-Myers Squibb Co (BMY, Financial) fell 3.90% in mid-day trading on Nov 16. The stock reached an intraday low of $55.82, before recovering slightly to $56.22, down from its previous close of $58.50. This places BMY 7.96% below its 52-week high of $61.08 and 42.87% above its 52-week low of $39.35. Trading volume was 20,863,120 shares, 175.3% of the average daily volume of 11,899,293.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Bristol-Myers Squibb Co (BMY, Financial) is $56.97 with a high estimate of $73.00 and a low estimate of $33.10. The average target implies an upside of 1.33% from the current price of $56.22. More detailed estimate data can be found on the Bristol-Myers Squibb Co (BMY) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, Bristol-Myers Squibb Co's (BMY, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bristol-Myers Squibb Co (BMY, Financial) in one year is $69.68, suggesting a upside of 23.94% from the current price of $56.22. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bristol-Myers Squibb Co (BMY) Summary page.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
